Multicenter Validation of a Gene Expression–Based Prognostic Signature in Lymph Node–Negative Primary Breast Cancer
Authors:
- John A. FoekensJFJohn A. Foekens
- David AtkinsDADavid Atkins
- Yi ZhangYZYi Zhang
- Fred C.G.J. SweepFSFred C.G.J. Sweep
- Nadia HarbeckNHNadia Harbeck
- Angelo ParadisoAPAngelo Paradiso
- Tanja CuferTCTanja Cufer
- Anieta M. SieuwertsASAnieta M. Sieuwerts
- Dmitri TalantovDTDmitri Talantov
- Paul N. SpanPaul N. Span
- Vivianne C.G. Tjan-HeijnenVTVivianne C.G. Tjan-Heijnen
- Alfredo F. ZitoAZAlfredo F. Zito
- 20 April 2006
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (11) , 1665-1671
Abstract
Purpose: We previously identified in a single-center study a 76-gene prognostic signature for lymph node-negative (LNN) breast cancer patients. The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions. Patients and Methods: Using custom-designed DNA chips we analyzed the expression of the 76 genes in RNA of frozen tumor samples from 180 LNN patients who did not receive adjuvant systemic treatment. Results: In this independent validation, the 76-gene signature was highly informative in identifying patients with distant metastasis within 5 years (hazard ratio, [HR], 7.41; 95% CI, 2.63 to 20.9), even when corrected for traditional prognostic factors in multivariate analysis (HR, 11.36; 95% CI, 2.67 to 48.4). The actuarial 5- and 10-year distant metastasis-free survival were 96% (95% CI, 89% to 99%) and 94% (95% CI, 83% to 98%), respectively, for the good profile group and 74% (95% CI, 64% to 81%) and 65% (53% to 74%), respectively for the poor profile group. The sensitivity for 5-yr distant metastasis-free survival was 90%, and the specificity was 50%. The positive and negative predictive values were 38% (95% CI, 29% to 47%) and 94% (95% CI, 86% to 97%), respectively. The 76-gene signature was confirmed as a strong prognostic factor in subgroups of estrogen receptor-positive patients, pre- and postmenopausal patients, and patients with tumor sizes 20 mm or smaller. The subgroup of patients with estrogen receptor-negative tumors was considered too small to perform a separate analysis. Conclusion: Our data provide a strong methodologic and clinical multicenter validation of the predefined prognostic 76-gene signature in LNN breast cancer patients.Keywords
This publication has 20 references indexed in Scilit:
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifenCancer Cell, 2004
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Breast cancer classification and prognosis based on gene expression profiles from a population-based studyProceedings of the National Academy of Sciences, 2003
- Gene expression predictors of breast cancer outcomesThe Lancet, 2003
- What's taking so long?Nature Genetics, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Identification of high risk breast-cancer patients by gene expression profilingThe Lancet, 2002
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI: Journal of the National Cancer Institute, 2001